-AstraZeneca will take full control of Caelum Biosciences in a deal worth up to $500 million, the drugmaker said on Wednesday ...
WILMINGTON, Del.--(BUSINESS WIRE)--Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine ...
4don MSN
BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment
BioMarin will acquire Alesta Therapeutics for $275 million upfront, bolstering BioMarin's unit focused on rare skeletal ...
An experimental drug from AstraZeneca succeeded in a late-stage trial in an autoimmune condition called generalized myasthenia gravis, positioning the company to grow a business it inherited when ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Lights, camera, Alexion! Fresh off earning FDA approval for its drug Ultomiris to treat certain adults with neuromyelitis optica spectrum disorder (NMOSD), AstraZeneca’s rare disease unit has put out ...
A year after debuting the “Rare Connections” series with a short film about patients’ experiences with neuromyelitis optica spectrum disorder (NMOSD), AstraZeneca’s rare disease unit is turning the ...
AstraZeneca, one of the frontrunners in the drugs industry's search for a COVID-19 vaccine, said on Saturday that Alexion shareholders would receive $60 in cash and 2.1243 AstraZeneca American ...
Pangaea Data, a company focused on detecting hard-to-diagnose diseases in patients, is partnering with Alexion, a subsidiary of AstraZeneca focused on treating rare diseases, to co-develop, clinically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results